235. 副甲状腺機能低下症 Hypoparathyroidism Clinical trials / Disease details
臨床試験数 : 88 / 薬物数 : 128 - (DrugBank : 25) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05239221 (ClinicalTrials.gov) | September 7, 2020 | 7/1/2022 | AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism | A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism | Chronic Hypoparathyroidism | Drug: AZP-3601;Drug: Placebo | Amolyt Pharma | NULL | Recruiting | 18 Years | 75 Years | All | 130 | Phase 1 | Hungary;Netherlands |